In October 2007, the provincial drug plan began covering the cholinesterase inhibitor medications (ChEIs: donepezil, galantamine, and rivastigmine) for patients with Alzheimer's disease (AD) as part of the Alzheimer's Drug Therapy Initiative (ADTI). Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.